House Passes FDA User Fee Reauthorization Bill

The bill reauthorizes the FDA’s ability to collect user fees for the review of prescription drugs, medical devices, generic drugs, and biosimilar biological products through 2022.

Read the full post at HIMSS News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive